-
Mashup Score: 1Hemostatic Techniques in the Management of Gastrointestinal Bleeding – Gastroenterology & Hepatology - 1 month(s) ago
“Potassium-Competitive Acid Blockers and Gastroesophageal Reflux Disease” with David Armstrong, MA, MB BChir… https://t.co/YawOvRycG4 “Examining the New Definition of Hepatorenal Syndrome and the Role of Terlipressin” with Robert S. Brown Jr, MD, MPH https://t.co/ETH9dEBCqq
Categories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 0
Cadman L. Leggett, MD Assistant Professor of Medicine Department of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota G & H How may artificial intelligence be used to help improve clinical or endoscopic evaluation of esophageal diseases? CL There are several aspects of how artificial intelligence (AI) is having and will continue to have an impact in the field of esophagology. Most algorithms to date have focused on enhancing endoscopic surveillance by improving detection of neoplastic
Categories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 4Current and Emerging Treatments for Autoimmune Hepatitis – Gastroenterology & Hepatology - 1 month(s) ago
Ethan M. Weinberg, MD, MS Assistant Professor of Clinical Medicine Division of Gastroenterology and Hepatology University of Pennsylvania Perelman School of Medicine Philadelphia, Pennsylvania G & H What is the current understanding of autoimmune hepatitis and its pathogenesis? EW Autoimmune hepatitis (AIH) is a composite of diseases marked by immune dysregulation targeting hepatocytes in the absence of infection. This immune dysregulation leads to inflammation in the liver. Clinically, this is seen as
Categories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 0Current Status of the Liver Imaging Reporting and Data System in Hepatocellular Carcinoma – Gastroenterology & Hepatology - 1 month(s) ago
Victoria Chernyak, MD, MS Professor of Radiology Weill Cornell Medical College Department of Radiology Memorial Sloan Kettering Cancer Center New York, New York Co-Chair of the LI-RADS Steering Committee G & H What are the current uses of the Liver Imaging Reporting and Data System in hepatocellular carcinoma, and what are its main categories? VC There are currently 3 main contexts of use for the Liver Imaging Reporting and Data System (LI-RADS) in hepatocellular carcinoma (HCC). One is surveillance, for
Categories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 0Corticosteroid-Free Remission in Patients With Inflammatory Bowel Disease – Gastroenterology & Hepatology - 2 month(s) ago
Bruno César da Silva, MD, MSc Coordinator of the Gastroenterology Division Research Physician at the Clinical Research Center Hospital da Bahia, Dasa Salvador, Brazil G & H Currently, when might corticosteroids be used in patients with inflammatory bowel disease? BS Corticosteroids remain an important element in the treatment of inflammatory bowel disease (IBD). Studies have demonstrated the efficacy of corticosteroids in rapidly controlling inflammatory activity in both ulcerative colitis and Crohn’s
Categories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 1
David Y. Graham, MD Baylor College of Medicine and Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas Corresponding author: Dr David Y. Graham Michael E. DeBakey Veterans Affairs Medical Center 2002 Holcombe Blvd Rm 3C-109 Houston, TX 77030 Tel: (713) 795-0232 E-mail: dgraham@bcm.edu Abstract: For decades, antimicrobial therapy for Helicobacter pylori infection has been given empirically, and the results of therapy (success or failure) have either not been confirmed or when confirmed have
Categories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 2Update on the Screening, Diagnosis, and Management of Cholangiocarcinoma – Gastroenterology & Hepatology - 2 month(s) ago
Sudha Kodali, MD Sherrie and Alan Conover Center for Liver Disease and Transplantation, J. C. Walter Jr Transplant Center, Houston Methodist Hospital, Houston, Texas Department of Medicine, Houston Methodist Hospital, Houston, Texas Department of Medicine, Weill Cornell Medical College, New York, New York Ashton A. Connor, MD, PhD Sherrie and Alan Conover Center for Liver Disease and Transplantation, J. C. Walter Jr Transplant Center, Houston Methodist Hospital, Houston, Texas Department of Surgery,
Categories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 1Current Issue – Gastroenterology & Hepatology - 2 month(s) ago
Abstract: Tremendous effort has been put forth over the past 2 decades in understanding the pathophysiology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH). Although multiple potential […] Abstract: Barrett esophagus (BE) is the only known precursor to esophageal adenocarcinoma (EAC), a cancer that continues to have a poor 5-year survival rate of 20%. […] G & H What led to the concept of a treat-to-target approach for the management of patients with inflammatory bowel
Categories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 0Reflecting on a Decade of Sofosbuvir Use for Hepatitis C Virus Treatment – Gastroenterology & Hepatology - 2 month(s) ago
Ira M. Jacobson, MD Professor of Medicine Director of Hepatology Research NYU Langone Health New York, New York G & H Sofosbuvir was approved with ribavirin or pegylated interferon plus ribavirin just over 10 years ago for the treatment of hepatitis C virus infection. Thinking back over the past decade of its use, why was sofosbuvir studied in this area in the first place? IJ Sofosbuvir is a nucleotide analog inhibitor of hepatitis C virus (HCV) NS5B polymerase. The drug mimics one of the normal building
Categories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 1Durvalumab Plus Tremelimumab for First-Line Treatment of Hepatocellular Carcinoma – Gastroenterology & Hepatology - 2 month(s) ago
Robin Kate Kelley, MD Professor of Clinical Medicine Division of Hematology/Oncology Helen Diller Family Comprehensive Cancer Center University of California, San Francisco San Francisco, California G & H What is the rationale for using durvalumab and tremelimumab in combination for the treatment of hepatocellular carcinoma? RK Durvalumab (Imfinzi, AstraZeneca) and tremelimumab (Imjudo, AstraZeneca) are both immune checkpoint inhibitors, but different ones. Durvalumab is an inhibitor of the programmed
Categories: General Medicine News, GastroenterologyTweet
“Hemostatic Techniques in the Management of Gastrointestinal Bleeding” with Seth A. Gross, MD https://t.co/G9Ci8jc3Qp @nyulangone